Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

54.94 +0.14 (+0.26%)
Streaming Delayed Price Updated: 2:46 PM EDT, Sep 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
38 39 Next >
News headline image
Stock Analysis: Roche Holding AG ↗
Roche is a Swiss biopharmaceutical and diagnostic company. 
Via Talk Markets
News headline image
3 Stocks That Are Reshaping the Future ↗
As the population ages and AI develops, these three companies stand out among stocks reshaping the future. 
Via InvestorPlace
News headline image
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
Sarepta Therapeutics soars 31% as FDA committee supports gene therapy for Duchenne muscular dystrophy. Analysts have a "moderate buy" rating on the stock. 
Via MarketBeat
News headline image
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC ↗
Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr.... 
Via Talk Markets
News headline image
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
News headline image
Is Roche a Buy Now? ↗
Roche focuses on the long-term. 
Via The Motley Fool
News headline image
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo. 
Via MarketBeat
News headline image
EXCLUSIVE: SAB Biotherapeutics' Influenza Immunotherapy Shows Safety, Efficacy In Early-Stage Trials ↗
SAB Biotherapeutics Inc (NASDAQ: SABS) has announced the presentation of safety and efficacy data from Phase 1 and 2a trials of its influenza immunotherapy, SAB-176. 
Via Benzinga
News headline image
Tempest Therapeutics' TPST-1120 Shines In Early Phase 1b/2 Study: Analysts Get Bullish ↗
Tempest Therapeutics Inc (NASDAQ: TPST) announced  
Via Benzinga
News headline image
Will Merck's Earnings Beat Give The Pharma Stock A Sorely Needed Boost? ↗
The company reported lighter-than-expected declines due to Keytruda and Gardasil. 
Via Investor's Business Daily
News headline image
Roche's Q1 Highlights: Increased Uptake Of Eye Disease Drug Cushions Sales Decline ↗
Roche Holdings AG's (OTC: RHHBY) first-quarter sales dropped 7% Y/Y (down 3% at constant currency)  
Via Benzinga
News headline image
Pharma Behemoths GSK, Roche Outplay Covid Declines To Beat Quarterly Calls ↗
Both GSK and Roche experienced declining Covid-related sales in the first quarter. 
Via Investor's Business Daily
News headline image
EXCLUSIVE: SAB Biotherapeutics Releases Topline Data From Discontinued COVID Antibody Trial ↗
SAB Biotherapeutics Inc (NASDAQ: SABS) has revealed topline results from the Phase 3 National Institutes of Health's (NIH) ACTIV-2 trial that assessed SAB-185 in non-hospitalized COVID-19 patients at... 
Via Benzinga
News headline image
New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
From Genentech
Via Business Wire
News headline image
3 Top Biotech Stocks Defying the Bear Market ↗
All three companies have therapies with strong sales potential. 
Via The Motley Fool
News headline image
This Company's Non-Invasive Tech Looks To Be Unique In the Market And Can Help People Take Ownership Over Monitoring Their Health ↗
The need for noninvasive healthcare technology that allows people to take ownership and gather more insight into their health became acute when COVID revealed the fragility of the hospital system.  
Via Benzinga
News headline image
Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting
From Genentech
Via Business Wire
News headline image
Biogen To Report Q1 Earnings: Here's What To Expect ↗
We expect Biogen to beat expectations when it reports first-quarter 2023 results on Apr. 25 before the market opens. In the last reported quarter, the company delivered an earnings surprise of 15.38%. 
Via Talk Markets
News headline image
FDA Approves Roche's Polivy Combo Therapy For Untreated Patients With Diffuse Large B-Cell Lymphoma ↗
 
Via Benzinga
News headline image
FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma
From Genentech
Via Business Wire
News headline image
Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study
From Genentech
Via Business Wire
News headline image
EXCLUSIVE: FDA Grants Expedited Review Status To SAB Biotherapeutics' Influenza Antibody ↗
The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ: SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those... 
Via Benzinga
News headline image
Trillions In Biotech Stock Gains Trace Back To This Financier ↗
Frank did not grow up as son of a Wall Street banker. He began as the consummate outsider. 
Via Investor's Business Daily
News headline image
Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023
From Genentech
Via Business Wire
News headline image
Why Shares of Adaptimmune Therapeutics Jumped Tuesday ↗
The company bulks up its pipeline by regaining the rights to two of its clinical programs. 
Via The Motley Fool
News headline image
Top-Notch Biotech TG Therapeutics Logs 'Solid Jump' In Sales; Shares Rocket ↗
Shares are closing in on a buy point out of a consolidation. 
Via Investor's Business Daily
News headline image
Bolt Biotherapeutics Says Phase 1 Data Supports Advancing Into Phase 2 Studies ↗
 
Via Benzinga
News headline image
Roche's Slow Growth Shouldn't Drive Investors Away ↗
New treatments for various cancers, eye diseases, and more may bring in future revenues. 
Via The Motley Fool
News headline image
Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease ↗
 
Via Benzinga
News headline image
New Four Year Data For Roche's Evrysdi Reinforces Long-Term Efficacy, Safety Profile In Muscular Atrophy Patients ↗
 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.